Trials / Unknown
UnknownNCT00563589
Mycophenolate Mofetil for the Prophylaxis of Graft-versus-host Disease in High Risk Allogeneic Stem Cell Transplantation
A Randomized Single-center Trial of Mycophenolate Mofetil for the Prophylaxis of Graft-versus-host Disease in High Risk Allogeneic Stem Cell Transplantation
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Hospital Authority, Hong Kong · Other Government
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
There is a significant (50-80%) risk of acute graft-versus-host disease(GVHD) and early mortality (30%) associated with high risk stem cell transplantation (SCT) such as that from a matched unrelated donor or HLA-mismatch sibling. Mycophenolate mofetil (MMF) has been shown to be an effective and safe immunosuppressant in the prevention and treatment of rejection after solid organ transplantation. Its role in acute GVHD prophylaxis in high risk SCT will be investigated in this clinical trial.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | mycophenolate mofetil, methotrexate, cyclosporin | |
| DRUG | Methotrexate and cyclosporin |
Timeline
- Start date
- 2003-08-01
- Completion
- 2008-12-01
- First posted
- 2007-11-26
- Last updated
- 2010-07-07
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT00563589. Inclusion in this directory is not an endorsement.